Sign in

CIK 0001157601

  • Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 267-824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
  1. 4 Open-market buy Director bought 25,016 shares at $3.94 ($98,473)
  2. 4 Open-market buy Director bought 8,000 shares at an average $3.98 ($31,832)
  3. 4 Open-market buy Director bought 54,640 shares at an average $3.79 ($207,219)
  4. 4 Open-market buy Director bought 153,234 shares at an average $3.79 ($580,158)
  5. 4 Open-market buy Director bought 96,457 shares at an average $3.84 ($370,503)
  6. 4 Open-market buy SVP, Chief Medical Officer bought 2,500 shares at an average $4.01 ($10,022)
  7. 4 Open-market buy Director bought 100 shares at $3.85 ($385)
  8. 4 Open-market buy Director bought 15,764 shares at an average $3.75 ($59,189)
  9. 4 Open-market buy Director bought 3,303 shares at $3.79 ($12,510)
  10. 4 Open-market buy Director bought 128,142 shares at an average $3.73 ($477,576)
  11. 4 Grant or award Director acquired 1,964 shares (grant or award)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Grant or award Director acquired 7,858 shares (grant or award)
  15. 4 Grant or award Director acquired 7,858 shares (grant or award)
  16. 4 Open-market sale Sr. VP, Drug Development sold 20,000 shares at an average $5.80 ($116,000)
  17. 4 Open-market buy Director bought 50,000 shares at $4.89 ($244,500)
  18. 4 Open-market buy Director bought 100,000 shares at $4.89 ($489,000)
  19. 4 Open-market buy Director bought 1,431,493 shares at $4.89 ($7,000,001)
  20. 4 Open-market buy President and CEO bought 5,000 shares at $4.45 ($22,250)

Page 22 of 29 · 564 filings